BI
MRTX

BVF Inc’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

BVF Inc’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-308,984
Closed -$24.1M – 61
2019
Q3 		$24.1M Sell
308,984
-218,269
-41% -$20.5M 2.53% 14
2019
Q2 		$54.3M Buy
527,253
+95,553
+22% +$7.44M 5.93% 5
2019
Q1 		$31.6M Sell
431,700
-257,151
-37% -$17.5M 3.54% 9
2018
Q4 		$29.2M Sell
688,851
-34,471
-5% -$1.37M 3.82% 6
2018
Q3 		$34.1M Sell
723,322
-21,678
-3% -$1.21M 2.99% 9
2018
Q2 		$36.7M Buy
+745,000
New +$28.1M 3.58% 8
2014
Q2 		– Sell
-74,900
Closed -$1.43M – 32
2014
Q1 		$1.43M Sell
74,900
-59,417
-44% -$1.23M 0.22% 25
2013
Q4 		$2.23M Sell
134,317
-411,055
-75% -$7.03M 0.39% 20
2013
Q3 		$8.26M Buy
+545,372
New +$5.36M 1.42% 16

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc's MRTX Position: Q4 2019 in Review

BVF Inc sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2019, closing a stake of 308,984 shares — an estimated $24.1M sold.

BVF Inc first reported a position in MRTX in Q3 2013 and held it in 9 quarters. The position peaked at $54.3M in Q2 2019. 190 funds tracked by Wall St. Rank hold MRTX as of Q4 2019.

  • BVF Inc reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • BVF Inc sold 308,984 Mirati Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $24.1M.
  • BVF Inc first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2013 and held it in 9 quarters.
  • BVF Inc's Mirati Therapeutics, Inc. Common Stock position peaked at $54.3M in Q2 2019.
  • 190 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2019.

Based on BVF Inc's 13F filing for Q4 2019, filed 14 Feb 2020.